Comparing Upfront Payments among Multinational, Mid-Sized European, and Japanese Drug Firms
Continuing our focus on the licensing styles of different types of in-licensors of biotechnology, this month looks at the upfront payments made to biotech partners by the top 10 multinational drug companies, mid-sized Europeans, and Japanese drug firms.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.